Iotron Medical and Canadian Isotope Innovations (CIIC) will produce the radioisotope copper-67 (Cu-67) for new cancer therapies.
This collaboration will increase the production capacity of facilities operated by CIIC in Saskatoon, Canada, making the radioisotope more widely available to international cancer researchers.
Though Cu-67 has long been known to be beneficial for personalized cancer therapy, it has been difficult to produce with sufficient quantity and purity using nuclear reactors or cyclotrons. A lack of a reliable supply of the radioisotope has prevented medical researchers from exploring its potential in new targeted cancer therapies, according to the company.
